Alzheimer’s disease robs patients of so much more than their health. It can rewire their personalities and undermine a ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

Antipsychotics are the best defense against relapse in schizophrenia, even though that protection often comes at the expense ...

There are many mechanisms at work here, but the blood sugar increase is probably secondary to the weight gain, rather than ...

Management of adverse events is a major concern of clinicians who use antipsychotic drugs. The incidence of motor side effects is dose dependent. Atypical antipsychotic drugs are less likely to ...

A new report that lists what it calls the best nursing homes in the US finds that top-rated facilities continuously excel ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

Investing.com - AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia ...

The worldwide growing occurrences of mental health disorders are significantly boosting the antipsychotic drugs market. An estimated 21% of U.S. adults have mental illness in 2023, which is over ...

Resulting data from 9,525 participants determined that while antipsychotics as a group showed slight cognitive benefits, no individual drug demonstrated a substantial advantage over placebo.